Phone
Address Talkabouturology, Nizhny Novgorod, Russia
Skype ukitcom
Email Talkabouturology@list.ru
                                    Talk about urology
Back to the list

Erleada (apalutamide) has shown a significant increase in overall survival in mHRPC.

Erleada (apalutamide) has shown a significant increase in overall survival in mHRPC. In the final analysis of the TITAN Phase 3 study, apalutamide demonstrated a consistent safety profile and statistically significant increase in overall survival among patients with metastatic hormone-sensitive prostate cancer.


https://roou.ru/preparat-erleada-apalutamid-prodemonstriroval-znachitelnoe-uvelichenie-obshhej-vyzhivaemosti-pri-mgchrpzh/?fbclid=IwAR3SDoFRuvVa2HnVfPJo0dxfjrWCjCb0LfHy7i5TE5WyqIPNfHlbGv4zJ9s#request